Association of outcome with early stroke treatment: Pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials

Lancet

Volumn 363, Issue 9411, 2004, Pages 768-774

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE;

AGE; ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; HAZARD ASSESSMENT; HUMAN; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PARENCHYMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TREATMENT PLANNING;

AGED; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PLACEBOS; RANDOMIZED CONTROLLED TRIALS; RECOMBINANT PROTEINS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 1542315556     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(04)15692-4     Document Type: Article

References (25)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 333:1995;1581-1587.
2. Hacke W, Kaste M, Fieschi C, et al. for the ECASS Study Group. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274: 1017-25.
3. Hacke W., Kaste M., Fieschi C., et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet. 352:1998;1245-1251.
4. Clark W.M., Albers G.W., Madden K.P., et al. The rt-PA (alteplase) 0- to 6-hour acute stroke trial, part A (A0267g): results of a double-blind, placebo-controlled, multicenter study. Stroke. 31:2000;811-816.
5. Clark W.M., Wissman S., Albers G.W., et al. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset: the ATLANTIS study - a randomized controlled trial. JAMA. 282:1999;2019-2026.
6. Marler J.R., Tilley B.C., Lu M., et al. Early stroke treatment associated with better outcome: the NINDS rt-PA Stroke Study. Neurology. 55:2000;1649-1655.
7. Wardlaw J.M., Sandercock P.A., Berge E. Thrombolytic therapy with recombinant tissue plasminogen activator for acute ischemic stroke: where do we go from here? - a cumulative meta-analysis. Stroke. 34:2003;1437-1442.
8. Haley EC Jr, Brott T.G., Sheppard G.L., et al. Pilot randomized trial of tissue plasminogen activator in acute ischemic stroke. Stroke. 24:1993;1000-1004.
9. Brott T., Adams H.P., Olinger C.P., et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke. 20:1989;864-870.
10. Scandinavian Stroke Study Group. Multicenter trial of hemodilution in ischemic stroke: background and study protocol. Stroke. 16:1995;885-890.
11. Mahoney F.I., Barthel D.W. Functional evaluation: the Barthel Index. Md State Med J. 14:1965;61-65.
12. Van Swieten J.C., Koudstaal P.J., Visser M.C., Schouten H.J., van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 19:1988;604-607.
13. Teasdale G., Knill-Jones R., Van der Sande J. Observer variability in assessing impaired consciousness and coma. J Neurol Neurosurg Psychiatry. 41:1978;603-610.
14. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Generalized efficacy of rt-PA for acute stroke: subgroup analysis of the NINDS rt-PA stroke trial. Stroke. 28:1997;2119-2125.
15. Baron J.C., von Kummer R., del Zoppo G.J. Treatment of acute ischemic stroke: challenging the concept of a rigid and universal time-window. Stroke. 26:1995;2219-2221.
16. Parsons M.W., Barber P.A., Chalk J., et al. Diffusion- and perfusion-weighted MRI response to thrombolysis in stroke. Ann Neurol. 51:2002;28-37.
17. Christou I., Alexandrov A., Burgin W.S., et al. Timing of recanalization after tissue plasminogen activator therapy determined by transcranial doppler correlates with clinical recovery from ischemic stroke. Stroke. 31:2000;1812-1816.
18. The NINDS t-Pa Stroke Study Group. Intracerebral hemorrhage following intravenous t-PA therapy for ischemic stroke. Stroke. 28:1997;2109-2118.
19. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet. 343:1994;311-322.
20. Chareonthaitawee P., Gibbons R.J., Roberts R.S., et al. The impact of time to thrombolytic treatment on outcome in patients with acute myocardial infarction. Heart. 84:2000;142-148.
21. Berger P.B., Ellis S.G., Holmes D.R., et al. Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: results from the global use of strategies to open occluded arteries in acute coronary syndromes (GUSTO-IIb) trial. Circulation. 100:1999;14-20.
22. Grouppo Italiano per lo Studio della Streptokinase nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; 1: 397-402.
23. Albers G., Bates V., Clark W., Bell R., Verro P., Hamilton S. Intravenous tissue-type plasminogen activator for treatment of acute stroke: The Standard Treatment with Alteplase to Reverse Stroke (STARS) Study. JAMA. 283:2000;1145-1150.
24. Marler JR, Winters-Jones P, Emr M, eds. Proceedings of a National Symposium on Rapid Identification and Treatment of Acute Stroke; 1997. Bethesda, Maryland; National Institutes of Health, National Institute of Neurological Disorders and Stroke: 157-58.
25. Tilley B.C., Lyden P.D., Brott T.G., et al. Total quality improvement methodology for reduction of delays between emergency department admission and treatment of acute ischemic stroke. Arch Neurol. 54:1997;1466-1474.